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Abstract: Emetine is a potent antiviral that acts on many viruses in the low-nM range, with several
studies in animals and humans demonstrating antiviral activity. Historically, emetine was used to treat
patients with Spanish influenza, in the last stages of the pandemic in the early 1900s. Some of these
patients were “black” with cyanosis. Emetine rapidly reversed the cyanosis and other symptoms of
this disease in 12–24 h. However, emetine also has been shown to have anti-inflammatory properties
and it appears it is these anti-inflammatory properties that were responsible for the effects seen in
patients with Spanish influenza. Emetine, in the past, has also been used in 10s to 100s of millions of
people at a dose of ~60 mg daily to treat amoebiasis. Based on viral inhibition data we can calculate a
likely SARS-CoV2 antiviral dose of ~1/10th the amoebiasis dose, which should dramatically reduce
the risk of any side effects. While there are no anti-inflammatory dose response data available,
based on the potential mode of action, the anti-inflammatory actions may also occur at low doses.
This paper also examines the toxicity of emetine seen in clinical practice and that seen in the laboratory,
and discusses the methods of administration aimed at reducing side effects if higher doses were
found to be necessary. While emetine is a “pure drug” as it is extracted from ipecac, some of the
differences between emetine and ipecac are also discussed.
Keywords: COVID-19; coronavirus; emetine; ipecac; dehydroemetine; treatment; re-purposing;
antiviral; anti-inflammatory; toxicity
1. Introduction
We previously discussed the potential use of emetine for the treatment of the SARS-CoV2
coronavirus, at 1/5th to 1/10th the amoebiasis treatment dose [1]. At the time of writing that article it
was not definitively known if emetine was active against SARS-CoV2. At least three studies have now
confirmed that SARS-CoV2 is sensitive to emetine [2–4], with a half-maximal effective concentration
(EC50) of ~0.5 µM. As discussed in the Supplementary File, this has enabled the calculation of a
treatment dose of 6 mg daily, which is 1/10th the normal amoebiasis dose.
Emetine was an important and effective anti-infective drug for the treatment of intestinal and
extraintestinal amoebiasis, between the mid-1910s to the 1970s. It was likely administered to 10s–100s
of millions of people in the treatment of amoebiasis (see Supplementary File). It was included in the
WHO Essential Medicine List until 1983 [5] and the emetine injection is still listed in the United States
Pharmacopeia [6]. Despite this, relatively few medical professionals today are familiar with it. A quick
online search reveals that emetine is extracted from ipecac. All would have heard of ipecac, and its
ability to induce emesis (vomiting). Most would know about the abuse potential of Ipecac Syrup in
those with Bulimia Nervosa, as well as Anorexia Nervosa, and that chronic dosing over months can
lead to cardiac toxicity and eventually death [7,8].
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However, emetine is not ipecac. Ipecac consists of the dried rhizome and roots of Cephaëlis acuminata,
or of Cephaëlis ipecacuanha [9,10]. There were at least 16 different alkaloids isolated from these plants [11].
Emetine, an ether soluble alkaloid, is generally less than 2% by weight of the dried ipecac root [12–14].
Early animal studies demonstrated that emetine was inappropriately named. Cephaeline, the other
ether soluble alkaloid extracted from ipecac, was found to be approximately twice as emetic as
emetine [15]. The United States Pharmacopeia (USP) specifies that the content of cephaeline in “Ipecac
Oral Solution” (Syrup of Ipecac) can range from an amount equal to, to an amount not more than
2.5 times, the content of emetine [16]. If these were the only alkaloids found in ipecac then the
majority of the formulation’s nauseating/emetic properties could be attributed to cephaeline and not
emetine. As an illustration, the first patient who was administered emetine by hypodermic injection
was a 29-year-old Japanese patient critically ill with amoebic dysentery and who could not tolerate
ipecacuanha—the standard treatment at the time. She was administered an emetine dose equivalent to
that contained in “75 grains of ipecacuanha, in sixteen and a half hours, without the slightest unpleasant effect
on the patient, who had been unable to retain 1 grain (of ipecacuanha) when administered by mouth” [17].
Emetine was shown to have significant antiviral and anti-inflammatory properties [18], and has
the potential to be a safe and effective antiviral agent at low doses. Based on the response of patients
with Spanish influenza treated with emetine (described below), it is perhaps the anti-inflammatory
properties of emetine that hold the most promise.
2. Emetine as an Antiviral
There is no question that emetine has potent antiviral actions, as exhibited by the numerous
in vitro studies on multiple viruses demonstrating EC50 values in the sub-µM and low-nM ranges,
see Table 1. It protected 67% of mice injected with 1000 times the mean lethal dose for 50% (LD50)
of mouse-adapted Ebola virus [19] and all mice injected 25 times the LD50 of enterovirus, EV-A71,
with the emetine group showing a million-fold reduction in viral titers in the fore and hind limbs [20].
As expected, all control animals died in both experiments.
Common structural features used to classify viruses, such as enveloped, non-enveloped, DNA or
RNA genome viruses, do not appear to affect sensitivity to emetine. Coronavirus, Rift Valley fever,
Dengue, Zika and Ebola viruses are all enveloped viruses [21–25] that are sensitive to emetine. Similarly,
the numerous enteroviruses that are non-enveloped are also sensitive to emetine [26]. Herpesviruses,
double-stranded DNA viruses [27–30], are as sensitive to emetine as the single-stranded RNA viruses
such as Enterovirus, Coronavirus, Rift Valley fever, Dengue, Zika and Ebola viruses [21–26]. Viruses
with positive or negative single-stranded RNA (+,−ssRNA) also appear to have similar sensitivities to
emetine. The Ebola, Human metapneumovirus and Rift Valley fever viruses, with −ssRNAs [22,25,31],
and the Coronavirus, Dengue, Zika viruses, with +ssRNAs [21,23,24], have similar sensitivities to
emetine. It is unknown if single-stranded DNA viruses have altered sensitivity toward emetine.
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Table 1. EC50 values of emetine against various viruses. The majority of the viruses have an EC50 value in the low-nM range. For comparison purposes the EC50 value
of Entamoeba Histolytica is included. Most viruses have an EC50 value 20–300 times less than Entamoeba Histolytica, indicating that much lower doses would be
required for antiviral treatment than the doses used for the treatment of amoebiasis. The half-maximal cytotoxic concentration (CC50) and the selectivity index (SI)
data is included to demonstrate that the in vitro toxicity, as represented by the CC50, varies dramatically and that the concentrations are often substantially lower than
the likely concentration achieved in practice see Supplementary File, Table S1. The in vitro CC50 appears to have little resemblance to what is seen in practice.
Virus EC50 µM Cell Line CC50 Assay CC50 µM SI (b) Reference Notes
Entamoeba Histolytica
11.8
Not a virus, included for comparison and
is based on the average EC50 data (n = 7)
from Burchard and Mirelman 1988 [32]
Coronaviruses
SARS-CoV2 0.50 Vero E6 Cell titer-Glo luminescent(Promega) 56.46 112.92 Choy et al., 2020 [2]
SARS-CoV2 0.52 Caco-2 ATP assay >20(see Notes)
>38
(see Notes) Ellinger et al., 2020 [4]
Tabulated data gave the CC50 as 1.13 µM,
graphed data did not approach CC50 at
20 µM
SARS-CoV2 0.47 Caco-2 Rotitest Vital(WST-8; Roth) >30 >63 Bojkova et al., 2020 [3]
HCoV-OC43 0.21 HCT-8 MTS >50 >238 Yang et al., 2020 [33]
HCoV-OC43 0.3 BHK-21 MTT assay 2.69 8.97 Shen et al., 2019 [34]
MERS-CoV 0.34 Vero E6 MTT assay 3.08 9.06 Shen et al., 2019 [34]
MERS-CoV 0.08 Vero Method not disclosed >25 >312.5 Ko et al., 2020 [35]
MERS-CoV 0.014 Vero E6 Not determined Dyall et al., 2014 [36]
SARS-CoV 0.051 Vero E6 Not determined Dyall et al., 2014 [36]
HCoV-NL63 1.43 LLC-MK2 MTT assay 3.63 2.54 Shen et al., 2019 [34]

















MTT Assay 8 242 Mukhopadhyay et al., 2016 [37]
herpesvirus-2 0.03 retinal pigmentepithelial cells Cell Tox Green reagent 1.12 37 Andersen et al., 2019 [38]
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Table 1. Cont.
Virus EC50 µM Cell Line CC50 Assay CC50 µM SI (b) Reference Notes
Enteroviruses
Echovirus 1 0.14 retinal pigmentepithelial cells Cell Tox Green reagent >30 >214 Andersen et al., 2019 [38]
EV-A71
(hand, foot, & mouth
disease in children)
0.049 RD Cells Cell Counting Kit 8 10 204 Tang et al., 2020 [20]
EV-D68
(can lead to severe
respiratory illness)
0.0187 RD Cells Cell Counting Kit 8 10 535 Tang et al., 2020 [20]
Echov-6 0.045 RD Cells Cell Counting Kit 8 10 222 Tang et al., 2020 [20]
CV-A16
(hand, foot, and mouth
disease in children)
0.083 RD Cells Cell Counting Kit 8 10 120 Tang et al., 2020 [20]
CV-B1 0.05 RD Cells Cell Counting Kit 8 10 200 Tang et al., 2020 [20]
Other Viruses
influenza A 0.13 retinal pigmentepithelial cells Cell Tox Green reagent >30 >230 Andersen et al., 2019 [38]
Tang [20] noted emetine had no effect on
rotavirus and influenza. Data was not




epithelial cells Cell Tox Green reagent 1 7 Anderson et al., 2019 [38]










(see Notes) Low et al., 2009 [39]
Infection reduced by more than 2.5 log
units in cells treated at 0.5 µM; >90% cell
viability at 10 µM, therefore SI must be
significantly higher than 20.
Zika 0.053 HEK293 Possibly ATPLite assayused in supplement. 0.18 3.4 Yang et al., 2018 [19]
Ebola 0.017 Vero E6 Not determined - - Yang et al., 2018 [19]
HIV <0.03 PBMC Propidium iodide stainingand flow cytometry 0.1 >3.3 Valadão et al., 2015 [40]
Two different cell lines obtained very
different results. As the EC50 for Ghost
Cells is significantly greater than the
EC50 for Entamoeba Histolytica, this
would be considered highly resistant
HIV 30–100 Ghost cells CellTiter-Blue reagent >360 >3.6 Valadão et al., 2015 [40]
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Table 2 summarizes the results of antiviral studies involving emetine in humans. Multiple authors
have documented their success with emetine treatment of shingles. Most used doses in the 1.2–3.6 mg
range given on alternate days for 3–7 injections. Common themes through the papers were: (1) emetine
treatment quickly and permanently relieves pain (pain relief often starts in several hours but can take
24–36 h before it goes away completely); (2) emetine accelerates healing of all skin conditions from the
shingles (especially if given early; healing times with emetine were halved in all age groups); and (3)
there is a distinct lack of postherpetic neuralgia with emetine therapy [18].
Hanisch 1963 [41] treated 26 patients with epidemic kerato-conjunctivitis (believed to be caused
by an adenovirus [42]) with 20–30 mg of emetine subcutaneously every other day for five injections.
In 24 patients with strongly impaired vision the visual acuity was considerably improved after five
emetine injections (one injection every other day), up to months after the initial infection.
From 1938 to 1967 over 600 cases of viral hepatitis in children aged between 1 and 12 years old were
treated with emetine at a dose of 1 mg/kg/day. In 100% of cases clinical cure was obtained between 7
and 14 days. No cases had prolonged illness or relapsed. None of the patients experienced undesirable
side effects, but patients had “immediate favorable effects on appetite and general good feeling” [43].
In the early 1960s, Dr Antonio Fusillo an Italian physician, noticed rapid regression of zoster
vesicles in patients being treated with emetine for amoebic dysentery. Through several animal
experiments over time he determined that only very low doses of emetine, compared to that used
for amoebic dysentery, where required to be an effective antiviral. [44,45]. Over the course of his
working life Fusillo treated thousands of patients [46] with various viral conditions, such as herpes
zoster, chickenpox, epidemic mumps, hepatitis, influenza and lymphocytic meningitis, viral respiratory
infections, measles, orchitis epididymitis, and recurrent herpes simplex diseases. The treatment dose
he used was predominantly 3 mg every 12 h for the first three doses and then 3 mg per day for up to
10 days depending on the response to treatment [44].
During the two Spanish flu epidemics in New Orleans, in October 1918 and January 1919, Points
treated 433 cases of influenza and 73 cases of flu pneumonia [47]. One feature of the epidemic noted
by Points was “extreme cyanosis, amounting to almost blackness”. Points’ description of his first patient
where he noticed the “antiviral” activity of emetine was:
“Along about January 20 (1919), I treated a case of flu pneumonia complicated by a ruptured appendix.
The patient developed acute nephritis, ran 20 per cent of albumen and passed large quantities of blood
from the kidneys. Having had some previous experience with intravenous injections of emetine in
renal hemorrhages, I injected 1/2 grain (~30 mg) emetine hydrochloride into his veins. I repeated
this dose in twelve hours and the effect was marvelous, the patient’s temperature dropped from 104◦
to 101◦, the hemorrhage ceased, his cough became better, and his pulse slowed down. The following
morning, patient’s temperature was normal and his general condition much improved. Two injections
were given that day with the results that patient’s cough subsided, the congestion of the kidneys passed
off, the albumen disappeared, his pulse returned to normal and he seemed cured of his toxemia” [47]
Points went on to describe the treatment of a group of patients:
“In the Emetine group I treated 65 cases 9 of which had pneumonia and 2 of which died. All of
these nine cases of pneumonia were given from one to two intravenous injections of emetine per day.
Purposely no quinin and aspirin were given and no antipyretic used. The result was the immediate
lowering of the temperature from “ . . . . . . the temperature from 104◦ to 103◦ (ranging between
103◦–104◦) to normal in from 12 to 24 hours, according as one or two doses of emetine per day were
given. The temperature did not rise again and the disease was under control from that time on . . . . . .
Several of these cases had edema of the lungs and were cyanosed until they were black . . . . . . but the
results after the intravenous injections of emetine were astonishing. The temperature became normal,
the cough subsided, the cyanosis disappeared, and the fight was won . . . . . . (he describes other
treatment used) . . . . . . But the remarkable result was the rapid control of the temperature and the
toxemia, and the rapid clearing up of the whole picture after the use of emetine” [47]
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Table 2. Emetine use as an antiviral agent in humans.
Year/s (*) Condition Number of Patients Dosing (**) Side Effects Notes Language [Reference]
1920 Spanish Influenza 10 pneumonia (severe)17 mild cases ~30 mg IV every 12−24 h; 6 doses None described
Within 24 h for severe cases: Fall in temperature,
reversal of “black” cyanosis, reversal of tachycardia,
reduction in coughing patients recovers (see notes
within main document). No effect in mild cases at all
English [47]
1937 Shingles 3 Escalating doses on same day ~1.2, 1.8,2.4 and 3 mg None described
Clear reduction in pain begins a few hours after first
injection, after 2−5 days blisters are parched and the
pain disappears completely
French [48]
1952 Shingles 47 [18] 2.4 mg SC alternate days for 2−3 days.Up to 3.6 mg for severe cases [49] Unknown This dosage regimen was reported elsewhere [49] French [50] (ˆ)
1953 Shingles >30 Unknown presumed low doses given Unknown
This was a thesis; 30 cases were submitted from another
author [49]. As it was a French thesis it was considered
impractical to obtain and translate in a reasonable
time frame
French [51] (ˆ)
1954 Shingles >40 Unknown presumed low doses given Unknown Was quoted as saying “cured quickly without any failure”more than 40 patients [49] French [52] (ˆ)
1954 Shingles 13 2.4 mg on 1st, 3rd and 5th day “No ocular complications were noted”
Confirming the results of [49] “the cessation of pain after
the first injection of emetine was truly spectacular and very
rapid drying of the vesicles since healing takes 8 days
was obtained” [53]
French [53]
1957 Shingles 31 1.2−3.6 mg SC daily, five injectionsat most
One patient vomited. No other
patients had the
“slightest discomfort”
One case out of the 31 was considered a failure. While
it healed, they believed for this case it followed the
natural evolution of the disease
French [54]
1958 Shingles 40 2.4−3.6 mg on 1st, 3rd and 5th day No side effects mentioned
Paper compered results with his past results and with
the literature: (1) quickly and permanently relieved
pain (2) accelerated healing of all skin lesions (3) no
postherpetic neuralgia in any patient
German [18]
1959 Shingles 160 “areas” treated, patientnumbers not given.
2.4−3.6 mg every other day max.
7 injections Few patients had nausea
Disappearance of cutaneous hyperesthesia (a sign of
success). Rapid drying of lesions 3 to 7 days.
Rapid regression of lymph node sensitivity. Sleep often





1 mg/kg SC up to 10 doses (10 was
never reached) None mentioned
With the application of the first dose the
symptomatology quickly subsided—between 3 and 7
days to clinical cure
Spanish [55]
1963 Epidemickerato-conjunctivitis 31 20−30 mg SC every other day, 5 doses. None mentioned
In 24/26 patients with strongly impaired vision the
visual acuity could be considerably improved after five
emetine injections (1 injection every other day)
Hungarian [41]
1964 Ophthalmic Shingles 41 1.2−2.4 mg SC every other day for4−6 injections None mentioned
Only six cases had no improvement. Blisters dried
quickly, pain resolved and no cases of postherpetic
neuralgia. This study noted quick resolution, however
appeared more slowly than other studies
Polish [56]
1968 Hepatitis 600 children 1 mg/kg SC for 7−14 days Perfectly tolerated, no undesirableside effects
100% cure rate, had an immediate effect on appetite





1000s [46] 3 mg every 12 h for the first 24 h then3 mg per day
Negligible. In relation to
amoebiasis doses it was
considered homeopathic
Over the course of his working life Fusillo treated
thousands of patients with this dosage regimen, he
believed it to be a very broad acting and effective
antiviral agent at relatively low doses
Italian [44–46]
(*) A single date refers to the publication date. (**) SC = Subcutaneous, IV = Intravenous; doses are a representation, often doses changed on the clinical situation. (ˆ) Reference was unable
to be obtained, information was obtained from one or more other articles. Bibliography reference details may not be reliable.
Pharmaceuticals 2020, 13, 428 7 of 17
However, there are hints that the response seen with emetine for the Spanish influenza virus,
was not due to an antiviral effect, but possibly through acting on the inflammation caused by the virus
and not the virus itself:
“I was so encouraged by the good effects of emetine, when given early enough, that I resolved to
use it in all the flu cases, the drug once a day to seventeen simple, uncomplicated cases with these
results: The emetine had no effect whatsoever on the non-complicated cases of influenza, not only not
reducing the fever, but not controlling any of the symptoms. The disease in these cases ran a course of
3 to 5 days. But none of these cases developed any complications whatsoever from the flu, whereas
some of the simple cases, that at first refused the intravenous injections of emetine, later on developed
pneumonia and were saved by the drug. One of these simple cases, that refused the injections developed
a good attack of cholecystitis, which was instantly relieved by the emetine treatment” [47]
If this effect was truly an anti-inflammatory effect, as apposed an ant-viral effect, it is most likely
less prone to the development of resistance. Larger studies would have needed to be undertaken to
determine if the administration of emetine to uncomplicated cases reduced the likelihood of severe
disease. Other noteworthy observations raised by Points:
“My mortality with the emetine series of cases was virtually nil, for the two cases that did die were
beyond hope when the drug was given. . . . . . . One had already been sick a week, and her family
persistently refused to let me use this treatment until the night before her death; and the other had been
sick five days before I got hold of her, and was already well advanced in pneumonia when given the
first dose. Even then the beneficial effects of the drug could be seen, the patient’s temperature dropped,
and they seemed better for a while, but the delirium and coma steadily grew worse and they passed off.
Each case treated with emetine received injections, given from twelve to twenty-four hours apart,
according as my time would permit my seeing the patient once or twice a day.
Unfortunately I did not use the emetine treatment sufficiently early in the epidemic to determine its
true value. The disease was on the wane when I began to use it, so whether or not it would produce the
same marvelous results in all cases as it did in these is a question.
This problem now presents itself to my mind: Is emetine a cure for the complicated cases of
Influenza?” [47]
3. Antiviral Mode of Action of Emetine
The mode of action (MOA) of emetine, as an antiviral agent, has not been fully elucidated. However,
the MOA may depend on the virus in question. For the coronaviruses, emetine interferes with the
viruses’ ability to infect a cell. Shen et al., 2019 performed viral infectivity studies and determined that
emetine was an entry inhibitor that blocked MERS-CoV infection almost completely [34]. compared
with that of the control, at 5 µM and with an EC50 value of 0.16 µM.
On the other hand, Yang et al., 2018, in order to understand the stage of the Zika virus life cycle
affected by emetine, varied compound treatment before, during, and after Zika virus inoculation [19].
For all three stages, emetine was found to have an EC50 in the low-nM range (~0.04 µM), partly
indicating that the antiviral effect is most likely post-entry and at the step of viral replication [19].
In further support of this argument Yang et al., 2018 also found that emetine directly inhibited the Zika
virus NS5 RNA polymerase activity, with an IC50 of 0.121 µM [19].
As a potential other MOA, Mukhopadhyay et al., 2016, for the human cytomegalovirus (HCMV),
found that inhibition by emetine depended on 40S ribosomal processing S14 (RPS14) binding to MDM2.
Emetine lead to a disruption of the HCMV-induced MDM2-p53 interaction. HCMV replicated similarly
in RPS14 knockdown or control cells, but emetine did not inhibit virus replication in the former cell
line. The interaction of MDM2-p53 was maintained in infected RPS14 knockdown cells despite emetine
treatment confirming a new mode of action [37].
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Tang et al., 2020 demonstrated, by methods described previously [57] that emetine blocks viral
IRES-driven translation by the enterovirus EV-A71 [20]. Viral internal ribosome entry sites (IRESs) are
unique RNA elements, which use stable and dynamic RNA structures that recruit ribosomes and drive
protein synthesis [58]. An increasing number of viruses were shown to initiate protein synthesis by a
cap-independent mechanism involving IRESs [20,59]. It is important to note that IRES translation is
mediated through the 40S ribosomal subunit [57–59].
Both Tang et al., 2020 [20] and Mukhopadhyay et al., 2016 [37] demonstrated, by different
methods, the key role of emetine’s interaction with the 40S ribosomal subunit in viral inhibition.
As the 40S ribosomal subunit is a human protein, there is a potential significant benefit with regards
to the development of resistance. Under normal circumstances if an antiviral drug interacts with
a viral protein, mutations and the development of resistance can happen quickly in RNA viruses.
This is for many reasons, including low-quality replication mechanisms, proofreading, and access to
post-replicative repair [20,60]. However, none of these factors affect the human 40S ribosomal subunit
as its production is dependent on relatively higher quality replication mechanisms, proofreading,
and access to post-replicative repair. Human proteins mutate more slowly than bacterial or viral
proteins. IRESs form intricate secondary and tertiary structures with pseudoknots [61,62] that make
direct contact with the 40S subunit [61]. Altering RNA sequences can alter the tertiary structure,
which offer the possibility of emetine resistance. It remains to be seen if these altered structures can
survive in the long term. Tang et al., 2020 [20] noted they could initially induce an emetine-resistant
EV-A71 phenotype within nine passages; however, emetine-resistant viruses were not found during
long-term treatment in the presence of emetine in cell culture, and mutant viruses did not emerge under
the pressure of emetine [20]. Unfortunately, this may not apply to the coronavirus as emetine appears
to affect the virus’ ability to infect a cell [34]. This mechanism may be dependent on an interaction
with a viral protein that has an increased likelihood of resistance development.
4. Actions of Emetine as an Anti-Inflammatory
In the treatment of herpes zoster infections emetine has demonstrated very consistent, rapid,
persistent and effective pain relief and wound healing, as demonstrated by numerous authors, at very
low doses—in the 2−7 centigrain (~1.2−3.6 mg) dosage range with many patients only requiring 1 or 2
doses and most given under five doses on alternate days [18,49,53,54,56].
Before the antiviral properties of emetine were known, Jorda and Rothschild 1958 [18] set out to
determine the mechanism of action of emetine that made it effective in the treatment of herpes zoster
infections. First, they tested the hypothesis that emetine was an analgesic by using the “hot plate test”.
Forty mice were placed on a glass base heated to 60 ◦C and the reactivity (attempt to jump up) was
assessed with and without emetine. Despite the high dose used, emetine had no effect. Emetine had no
analgesic properties [18]. Jorda and Rothschild, in 1958m performed a series of experiments injecting
inflammatory substances into the plantar aponeurosis of the rear paw of Wistar rats and monitoring
how well emetine reduced inflammation relative to control rats. The three substances were: diluted
egg white, hyaluronidase, and formalin. Two hours after the egg white injection emetine (5 mg/kg) had
reduced the swelling (p ≤ 0.05) relative to control. Emetine also significantly reduced (~34%; p < 0.01)
the swelling induced by hyaluronidase relative to control. The formalin inflammation experiment
was monitored for changes in induced inflammation at multiple time points during the first seven
hours and the following 10 days. From this last experiment the anti-inflammatory effects increased
and peaked in the seventh hour, closely matching the latency seen in patients treated for shingles [18].
Furthermore, monitoring over 10 days showed significantly less skin ulcerations and swelling in the
emetine group than those in the control group [18]. Another study found that emetine (0.05 mg/kg/day;
4 weeks) significantly reduced the secretion of cytokines/chemokines and growth factors (e.g., IL-1β,
IL-6, and TNF-α) in Sugen/hypoxia-induced pulmonary hypertensive rats [63].
Several studies looked at the action of emetine on interferon/s and various aspects of the immune
system [64–71]. It is beyond the scope of this article to extrapolate data from one or more isolated,
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“interferon” or the like, in vitro, or in vivo studies to explain a clinical observation. Suffice to say that it
is well known that emetine inhibits protein synthesis and this action is understood to be responsible for
the amoebicidal action of emetine [72–74]. It is also known, as described above, that emetine interacts
with the 40S subunit of the human ribosome to inhibit viral protein synthesis. It is highly possible that
the action of emetine on protein synthesis would affect the production of multiple interferon proteins
and other immune-altering proteins. It would not be unreasonable to assume that it is this action,
at least in part, that is responsible for the anti-inflammatory activity of emetine.
To further support this argument it was shown that the human mTOR (central regulator of
immune responses) [75] transcript can be translated in a cap-independent manner that forms an RNA
scaffold capable of binding directly to the 40S ribosomal subunit [76].
5. Toxicity of Emetine
The toxicity emetine will be described in terms of the toxicity likely to be seen in clinical practice
and the toxicity seen in the laboratory.
5.1. Toxicity of Emetine in Clinical Practice
The toxicity of emetine, like most drugs, is dose-related. With a long biological half-life it can
accumulate, and that accumulation does increase the risk of toxicity. This toxicity of emetine will be
explored in terms of low and high doses of emetine. Low doses will be defined as doses less than 6 mg
(with many studies only using ~3 mg) of emetine daily. The majority of studies employ doses of less
than 6 mg per day. High doses will be defined as between ~20 mg and 60 mg. When emetine was used
widely, the increased risk of emetine toxicity in the elderly/frail was very much recognized and usually
warranted a reduction of the amoebiasis dose by at least half (~30 mg or less). In some situations,
emetine would have been contraindicated but at times there was little choice, especially with regards
to treating liver abscesses.
The information below is not intended to be a replacement for appropriate prescribing information
or other drug monographs.
5.1.1. Cardiac Toxicity
Low dose: No study referenced in this paper using low dose emetine highlighted a cardiac concern.
High dose: Cardiac toxicity has traditionally been the largest concern of emetine therapy. Yang et al.
1980 reviewed the cardiovascular side effects of therapeutic doses of emetine, concluding that
cardiac toxicity frequently included ECG changes and hypotension (discussed below) and occasionally
tachycardia and precordial pain. These changes occur during treatment or after completion of treatment
and often last a period of time. The patient usually recovers without any change in cardiovascular
function [77].
ECG changes, particularly flattening or inversion of the T-wave and prolongation of the Q-T
interval, occur in many (25−50%) patients [78,79]. However, cardiac disease and renal disease (likely
due to the risk of drug accumulation) are generally considered contraindications.
5.1.2. Hypotension
Low dose: the only study that mentioned blood pressure at all was Griveaud and Achard 1959
who described the hypotensive effect as minimal and of a short duration (“not durable”) but believed
it was important to monitor [49].
High dose: It is said that the hypotension from emetine is rarely marked [78]. However, the risks
associated with patients who are frail, elderly, and potentially the risk of co-existing hypotension
from viral septicemia would be higher. Harinasuta 1951, described a marked fall in blood pressure
(no values given) and severe prostration with rapid pulse in 5 out of 45 patients with the majority
treated with 30 or 60 mg of emetine daily for amoebic liver abscesses. After intravenous injection
blood pressure starts to drop 15−20 min after the injection [80]. Klatskin 1948 reported a fall in systolic
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pressure of 15 to 20 and the diastolic 5 to 10 mm of mercury in ~30% of patients [81]. In a previous
article by Klatskin, in treating over 500 servicemen, he commented “Occasional patients exhibited a fall
in blood pressure, rarely more than 15 or 20 mm. of mercury, which usually occurred between the sixth and
ninth doses” [82]. Unlike low-dose emetine the high-dose effect on blood pressure may be for a longer
duration, with Harinasuta pausing treatment for 5 days in one patient and 13 days in another [80].
5.1.3. Nausea
Low dose: Very few of the studies using low-dose emetine reported any nausea. Most noted that
there was no nausea or did not comment on it at all. Griveaud, reporting on 5 years’ experience with
emetine, noted that a few of the patients had some nausea [49]. One study with 31 patients reported
that one patient vomited, with all other subjects without the slightest discomfort [54].
High dose: The incidence of nausea in patients taking ameobiasis doses of emetine are highly
variable. Heilig [83] commented that in his study of 45 patients that: “not a single case suffered from
nausea, vomiting or toxic diarrhea, from neuritis or muscular weakness” and suggested that “it is possible that
these favorable results are partly due to the absence of toxic contaminations (cephaeline) in the brand of emetine
that is used in our hospital”. On the other hand, Klatskin 1948 [81], with 100 subjects, had one of the
highest incidences of nausea: “Nausea occurred in almost a third of the subjects and was only occasionally
accompanied by vomiting. In many it appeared within two hours of an injection and subsided rapidly, but in
others it was more persistent”. Interestingly, this study used several commercial preparations of emetine
hydrochloride [81].
Nausea from the ipecac alkaloids is relatively easy to treat. The emetic effects of ipecac syrup
(30 mL) can be completely eliminated, and nausea significantly reduced, by the use of 5HT3 antagonists,
such as ondansetron [84]. Emetine has a high affinity for the 5HT4 receptor with little activity on
5HT3 [85]. However, it should at least be considered that they could interact until in vitro studies can
confirm otherwise.
5.1.4. Pain on Injection
Pain on injection is included because it is a common feature of both subcutaneous and intramuscular
injection and for low and high doses of emetine. In relation to intramuscular injections (high dose);
pain can be almost immediately after injection and disappear in a few hours, but in the others the pain
may not appear until a day or two later. There can be local tenderness, poorly localized, constant aching
of the injected muscle, or more commonly, of all the surrounding muscles. The aching and tenderness
usually lasts for several days to a week after treatment is stopped. Emetine is rarely discontinued
because of pain [82].
5.2. Method of Administration and Toxicity
Traditionally, the preferred routes of emetine administration are by deep subcutaneous or
intramuscular injection. The intravenous use of emetine was considered contraindicated because it was
thought to be too dangerous and offered no therapeutic advantage [78]. However, there are advantages
of intravenous and subcutaneous infusions in the intensive care unit (ICU) setting. Infusions given
over many hours may reduce the incidence of side effects. If side effects occur, including adverse
changes in electrocardiography (ECG) or blood pressure, the rate of administration can be reduced
or stopped. It was observed that emetine solutions of less than 0.2%, produce little local effects [86].
A dilution of 30 mg emetine in 20 mL (0.15%; 1/20th of the normal intramuscular concentration) may
be able to be administered subcutaneously over many hours. No efficacy or safety data of slow emetine
infusions were found. Caution is warranted.
Parmer and Cottrill 1949 observed that soon after injection of emetine in rabbits, the heart levels
were relatively high, but after 6 h had dropped off to the low levels seen over the next 6 days [87].
To reduce peak concentrations of emetine in the heart, if high doses need to be given, infusion times of
greater than 6 h for 30 mg should be considered, especially in the old and frail.
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For low-dose emetine a 6 mg dose could be given, subcutaneously or intramuscularly, in divided
doses to minimize risk.
5.3. In Vitro Toxicity
Table 1 lists in vitro antiviral studies of emetine with corresponding EC50 and, where determined,
half-maximal cytotoxic concentration (CC50) values and the selectivity index (SI; SI = CC50/EC50)
calculated. The CC50 values show a large degree of variation depending on the type of CC50 test,
cell line and the duration of drug exposure.
There is a large disparity between the toxicity seen in the laboratory to what is seen in practice.
For example, looking at the number of studies in Table 1 that have CC50 values of 8 µM and less,
and comparing those values to the conservative tissue concentrations achieved in Supplementary File,
Table S1, there are four major organs that achieve tissue concentrations of emetine over three times
the CC50.
There are several reasons that could account for these discrepancies. Several CC50 tests use
a method that indirectly measures metabolic activity (i.e., MTT) or determines cell proliferation
(cell counting). It is assumed that a decrease in metabolic activity or a proliferation is an indicator
of cell toxicity or death. This is not always the case. Emetine is a protein synthesis inhibitor known
to inhibit the 40S subunit of a ribosome [88,89]. This type of drug would reduce metabolic activity,
and cellular proliferation but does not necessarily result in cell death. Bacteriostatic antibiotics behave
in a similar fashion and reduce bacterial metabolic activity and proliferation without necessarily killing
the bacteria. Examples would include the antibiotics doxycycline, chloramphenicol, and erythromycin
which also inhibit protein synthesis by interfering with the 30S/50S subunits of the ribosome [90].
Another limitation of CC50 tests, in relation to emetine, is the cell lines used to determine
toxicity. Emetine is well known to exhibit anti-cancer properties [91,92]. The cell lines used in the
CC50 are immortal cell lines, arguably sharing several characteristics of cancer. Their sensitivity to
emetine could depend on how the cells were immortalized (i.e., isolation from cancer cell, type of
viral immortalization). Toxicity seen in these cell lines may not be reflective of what happens to
non-cancerous cell lines in vivo. This action is also seen in non-cancer cell lines. Emetine was
shown to inhibit hyper-proliferating pulmonary artery smooth muscle cells (PASMCs) from rats
with pulmonary hypertension, normalizing proliferation/apoptosis. However, emetine had minimal
effect on non-hyper-proliferating PASMCs. This action was hypothesized to be due in part to the
normalization of hypoxia-inducible factors under hypoxic conditions [63].
Overall, the value of in vitro CC50 and SI data, in the case of emetine as an antiviral, is of little
value. Emetine has been used extensively in millions of humans over many years for the treatment
of amoebiasis and the more relevant in vivo toxicity is well described and understood. Furthermore,
as the antiviral and potentially anti-inflammatory doses being suggested are substantially lower than
that used for the treatment of amoebiasis any toxicity will be significantly lower.
6. Discussion
This paper, following on from our previous work [1], further explores the use of emetine as an
antiviral agent and addresses some preconceived notions that people would have when they first learn
that emetine is obtained from ipecac. Furthermore, the paper estimates the antiviral dose required
to be effective against SARS-CoV2 and gives a means to calculate the likely effective dose of emetine
against other viruses, based on viral inhibitory EC50 data (Supplementary File).
The likely antiviral dose for emetine is approximately 6 mg daily (given as a single or divided
doses) for SARS-CoV2. At this low dose, the side effects associated with the normal treatment dose
of amoebiasis are unlikely to be a clinical problem. Traditional contraindications of kidney or heart
disease are also much less likely to be an issue. Based on EC50 data, the dose required for the treatment
of non-coronaviruses viruses is likely to be substantially lower than 6 mg, reducing the risk of toxicity
even further.
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The rapid reversal of cyanosis seen with Spanish influenza appeared to be an effect independent of
emetine’s antiviral activity. If anything, the Spanish influenza virus was arguably resistant to emetine,
with no decrease in temperature or a reduction of any symptoms or shortening of the length of the
disease in mild cases. Added to that a patient’s cholecystitis pain being relieved by emetine further
suggests an anti-inflammatory response, given that emetine has no analgesic properties [18]. There is
growing recognition that the hyperinflammatory response induced by SARS-CoV-2 is a major cause of
disease severity and death in the infected patient [93–96]. If emetine could reduce the inflammatory
response in the SARS-CoV2 patient in the same way it appeared to in patients with Spanish influenza,
then the anti-inflammatory effect of emetine may be more important than the antiviral effect. This then
raises several questions that should be addressed.
At what dose are you likely to see an anti-inflammatory effect? In this article, we hypothesized
that the anti-inflammatory MOA is the same as the antiviral and anti-amoebic MOA—through the
inhibition of protein synthesis—in particular, binding to the human 40S subunit of the ribosome. If this
is correct then the anti-inflammatory doses may be very similar to the antiviral doses (low). However,
the effect seen by Points [47] for the treatment of Spanish influenza was seen at 30–60 mg per day.
Is a loading dose necessary? Loading doses were never used for the treatment of amoebiasis.
It would not have been possible to safely administer such large doses. For antiviral doses a single
large dose could be a loading dose or, because of its long biological half-life, a sustained-release dose.
However, it is unknown if RNA needs to be detached from the 40S subunit in order for emetine to
attach. If this is the case multiple doses may have a better outcome.
What is the likely duration of therapy? Emetine protein synthesis inhibition is considered
irreversible [97,98]. Therefore, not many doses may need to be given. Fusillo, who treated numerous
viral diseases at 3 mg every 12 h for the first 24 h and then 3 mg daily, found that 10 days was sufficient
for any viral disease [45], but many authors comment on a noticeable improvement between a couple
of hours to a few days.
What alternatives are there to emetine? A potential alternative to emetine is the very structurally
similar, and completely synthetic dehydroemetine. An injection form of dehydroemetine is still
available in India from Tablets India Limited, under the brand name Tilemetin. It is currently unknown
if this agent has similar antiviral and anti-inflammatory properties, and it should be tested if emetine is
found to be effective. Dehydroemetine is believed to be safer agent than emetine in terms of cardiac
toxicity [99]. Glaxo, in the 1960s, developed an oral dehydroemetine resinate preparation that was well
tolerated [100,101].
Can emetine be used in combinations with other drugs to improve antiviral efficacy or reduce side
effects? The concept of antiviral synergism is well known and understood. With regards to emetine,
Choy et al., 2020 demonstrated that emetine and remdesivir, when used in combination, displayed
significant antiviral synergism [2]. This implies that these drugs could be used at lower doses to
potentially reduce overall side effects without compromising the antiviral efficacy. However, if the
dominant therapeutic effect of emetine therapy is an anti-inflammatory effect it could be potentially
unwise to reduce the dose of emetine, especially if the anti-inflammatory action is already at a low dose.
If emetine proves to be successful for the treatment of SARS-CoV2, either as an antiviral or an
anti-inflammatory agent, then this would place a huge stress on wild populations of Cephaëlis acuminata
or Cephaëlis ipecacuanha from which emetine can be obtained. While these plants are commercially
grown, similar wild species/varieties are endangered [12,13]. There simply would not be sufficient
plant material to treat all that that would require it. Ultimately, and quickly, emetine would need to
be produced commercially and synthetically. Fortunately, this process has been established since the
1960s [102–104].
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7. Conclusions
Emetine, shows promising antiviral and anti-inflammatory properties. The use of low-dose,
or even, high-dose emetine should be considered in the treatment of COVID-19. Other viruses are far
more sensitive to the effects of emetine than SARS-CoV2, for which emetine may prove useful.
Supplementary Materials: The Supporting File is available online at http://www.mdpi.com/1424-8247/13/12/428/s1.
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